Skip to main content
. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169

Figure 4. Anti-angiogenic and therapeutic effects of miR-192 in orthotopic mouse models of ovarian cancer.

Figure 4

(a) Aggregate mass of intraperitoneal implanted SKOV3ip1-NC and SKOV3ip1-miR192 tumours (n=10, Student's t-test). (b) Effect of miR-192 expression on MVD and vessel pericyte coverage in SKOV3ip1 tumours (n=5, Student's t-test). Higher magnification images are shown in the insets. (c) Effect of miR-192-DOPC treatment on tumour weight in SKOV3ip1 tumour-bearing mice (n=10, Student's t-test). (d) Histopathological examination of major organs following 4 weeks of control miRNA-DOPC or miR-192-DOPC therapy (n=3). (e) Tumoral EGR1 and HOXB9 levels following two doses of control miRNA-DOPC or miR-192-DOPC therapies in SKOV3ip1 tumours (n=5, Student's t-test). (f) The effects of B20, control miRNA-DOPC or miR-192-DOPC on tumour burden in mice bearing OVCA-432 tumours (n=10, student t-test). (g) The impact of miR-192-DOPC on tumour burden in orthotopic SKOV3-EV, EGR1, HOXB9 and EGR1+HOXB9 tumours (left, n=10, Student's t-test). Representative images are shown (right; white circles: tumours). (h) Representative images of CD31 (red), desmin (green) and nuclei visualized with Hoechst 33342 (blue) in SKOV3ip1-EV and EGR1+HOXB9 tumours. Higher magnification images are shown in the insets. Bar graphs (right) show the quantitative analyses of CD31 and desmin staining (n=5, Student's t-test). Bars and error bars represent mean values and the corresponding s.e.m. (*P<0.05; **P<0.01; ***P<0.001; and ****P<0.0001).